Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab

  1. Motzer, R.
  2. George, S.
  3. Merchan, J.R.
  4. Hutson, T.E.
  5. Song, X.
  6. Perini, R.F.
  7. Xie, R.
  8. Bapat, U.
  9. Puente, J.
Revue:
Oncologist

ISSN: 1549-490X,  1083-7159

Année de publication: 2023

Volumen: 28

Número: 6

Pages: 501-509

Type: Article

DOI: 10.1093/ONCOLO/OYAC269 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus